Obstetrics and Gynecology · 2009 · 74 citations · 21 references
MedicineGynecologyInfectious DiseasesCytopathologyHiv PreventionReproductive HealthAntiretroviral TherapyCervical CytologyCervical LesionsCervical PathologyHiv EpidemiologyHuman Papillomavirus InfectionAntiretroviral Therapy CoverageCervical Lesion ProgressionCervical Squamous LesionsHpv ClearanceHuman Papillomavirus CytologyHuman Papillomavirus StatusPap Test CytologyRegression Of Cervical Lesions
OBJECTIVE: To examine the association of highly active antiretroviral therapy (HAART) with human papillomavirus (HPV) clearance and progression or regression of cervical cytological abnormalities in women with human immunodeficiency virus (HIV). METHODS: Five hundred thirty-seven women with HIV participating in the HIV Epidemiology Research Study, an observational, multisite cohort study, were evaluated semiannually from 1996 to 2000. Cervical Pap tests were collected for cervical cytology. Testing for HPV was conducted by polymerase chain reaction. Cox proportional hazard models were used to calculate hazard ratios and 95% confidence intervals (CIs). Number needed to treat (NNT) at 2 years was calculated for HAART. RESULTS: Among women with cervical squamous intraepithelial lesions, HAART was associated with an increased likelihood of HPV clearance (hazard ratio 4.5, 95% CI 1.2-16.3, NNT 22.4). Use of HAART was not associated with an increased likelihood of HPV clearance among women with normal cervical cytology (hazard ratio 1.7, 95% CI 0.9-3.1, NNT 6.5) or atypical squamous cells of undetermined significance cytology (hazard ratio 1.0, 95% CI 0.4-2.5, NNT 174.0). Use of HAART was not significantly associated with an increased likelihood of cervical cytologic regression (hazard ratio 1.3, 95% CI 1.0-1.7, NNT 10.9) or cervical cytologic progression (hazard ratio 0.7, 95% CI 0.6-1.0, NNT 12.8). CONCLUSION: Among women with preexisting abnormal cervical cytology, HAART was associated with enhanced HPV clearance but not with Pap test regression. Close monitoring of women with HIV for cervical cytologic abnormalities, regardless of HAART treatment status, is warranted. LEVEL OF EVIDENCE: II.
21
Incidence of Cervical Squamous Intraepithelial Lesions in HIV-Infected Women
Tedd V. Ellerbrock · JAMA · 2000 · 483 citations
The 1988 Bethesda System for Reporting Cervical/Vaginal Cytological Diagnoses
JAMA · 1989 · 470 citations
Medicine, Gynecology, Pathology +14
Linda Ahdieh, Robert S. Klein, Robert D. Burk et al. · The Journal of Infectious Diseases · 2001 · 326 citations
Thomas C. Wright, Tedd V. Ellerbrock, Mary Ann Chiasson et al. · PubMed · 1994 · 298 citations
Medicine, Gynecology, Pathology +17